Vote Scores

Home / Companies / Reata Pharmaceuticals, Inc. / 21 Sep 2023

Meeting · year to 30 June 2024360 filers reporting

Reata Pharmaceuticals, Inc.: meeting of 21 Sep 2023

Votes reported on Form N-PX, item by item

360 Form N-PX filers reported votes at the Reata Pharmaceuticals, Inc. meeting of 21 Sep 2023. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

3 vote records from 3 filers. 1 of the 3 filers that marked the item either way voted against management.

66.7% for33.3% against33.3% against management3 filers99.8% for0.2% against0.2% against management596,503 reported shares
2

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on pay tied to a merger or sale

525 vote records from 350 filers. 259 of the 331 filers that marked the item either way voted against management. 19 filers reported this item without a management mark.

3 filers reported share counts too large to be the holding described. No share split is published for this item. How that is decided

19.4% for72.9% against7.7% other78.2% against management350 filers
3

EXTRAORDINARY TRANSACTIONSIssuer

EXTRAORDINARY TRANSACTIONS: management items

Management items in this category are shown together; filers word and number them differently.

205 vote records from 108 filers. 0 of the 107 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

98.1% for0.0% against1.9% other0.0% against management108 filers100.0% for0.0% against0.0% other0.0% against management13,682,164,142 reported shares, counted once per item in this group
4

CORPORATE GOVERNANCEIssuer

CORPORATE GOVERNANCE: management items

Management items in this category are shown together; filers word and number them differently.

270 vote records from 127 filers. 10 of the 126 filers that marked the item either way voted against management. 1 filer reported this item without a management mark.

89.8% for7.9% against2.4% other7.9% against management127 filers100.0% for0.0% against0.0% other0.0% against management13,683,513,379 reported shares, counted once per item in this group

How the largest families voted

Family2. Merger pay
VanguardAgainst *
BlackRock and iSharesAgainst *
FidelityAgainst *
DimensionalAgainst *
State Street and SPDRAgainst *
American CenturyAgainst *
Franklin TempletonAgainst *
InvescoAgainst *
EquitableAgainst *
Charles SchwabAgainst *
Nuveen and TIAAAgainst *
ProShares and ProFundsAgainst *
John Hancock and ManulifeAgainst *
Morgan Stanley, Eaton Vance and CalvertAgainst *
J.P. MorganAgainst *
Goldman SachsAgainst *
PGIM and PrudentialFor
Jackson National fundsAgainst *
Northern Trust and FlexSharesAgainst *
SEIAgainst *
T. Rowe PriceAgainst *
Lincoln FinancialAgainst *
VoyaAbstain or withhold *
First TrustAgainst *
NationwideAgainst *
Victory CapitalAgainst *
Brighthouse FundsAgainst *
Guggenheim and RydexAgainst *
Columbia ThreadneedleAgainst *
BNY MellonAgainst *
PrincipalFor
Pacific Life fundsAgainst *
AllianceBernsteinAgainst *
DWSAgainst *
PIMCOAgainst *
MassMutualAgainst *
VirtusFor
Janus HendersonFor
Neuberger BermanFor
BairdAgainst *

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Reata Pharmaceuticals, Inc. meeting?

360 Form N-PX filers reported votes at the meeting of 21 Sep 2023. On say-on-pay, 1 of 3 voted against management (33.3%). The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Reata Pharmaceuticals, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Reata Pharmaceuticals, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Reata Pharmaceuticals, Inc. with a meeting date within three days of 21 Sep 2023. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.